肠促胰素类药物在减重中的临床应用及新药研究进展 点击下载
| 论文标题： | 肠促胰素类药物在减重中的临床应用及新药研究进展 |
| 英文标题： | |
| 中文摘要： | 肠促胰素类药物通过模拟或增强内源性肠促胰素信号，在体重管理和代谢疾病治疗中展现出重要临床价值。该类药物主要靶向胰高血糖素样肽-1受体、葡萄糖依赖性促胰岛素释放多肽受体及胰高血糖素受体等，经由中枢摄食调控、胃肠功能调节及外周代谢调节等多重机制发挥减重作用，并进一步改善血糖、血脂、脂肪肝及心肾代谢。本文以肠促胰素类药物为研究核心，重点梳理国内已上市及在研候选药物在减重领域的临床应用要点与相关研究进展。现有证据表明，司美格鲁肽、替尔泊肽减重幅度显著，兼具多重代谢获益；以玛仕度肽、埃诺格鲁肽等为代表的国产创新药物亦展现出良好的减重效果与安全性。在安全性方面，该类药物整体耐受性良好，常见不良反应主要为轻中度胃肠道反应，需关注胆囊事件、胰腺炎及情绪变化等潜在风险。儿童和青少年、老年人及妊娠期妇女等特殊人群用药需个体化评估。未来研究应聚焦于疗效预测生物标志物的筛选、长效口服制剂的开发及长期安全性随访数据的积累。 |
| 英文摘要： | Incretin-based drugs have demonstrated significant clinical value in weight management and the treatment of metabolic diseases by mimicking or enhancing endogenous incretin signaling. These agents primarily target multiple receptors including glucagon-like peptide-1， glucose-dependent insulinotropic polypeptide， and glucagon， exerting weight-reducing effects through multiple mechanisms such as central appetite regulation， gastrointestinal function modulation， and peripheral metabolic improvement， while further ameliorating blood glucose， blood lipids， fatty liver， and cardiorenal metabolic risks. This review focuses on incretin-based drugs， systematically summarizing the key clinical application points and relevant research progress of domestically marketed and investigational candidate drugs in the field of weight reduction. Available evidence indicates that semaglutide and tirzepatide demonstrate substantial weight reduction with multiple metabolic benefits； domestic innovative drugs represented by mazdutide and ecnoglutide also exhibit favorable weight-reducing effects and safety profiles. Regarding safety， these agents are generally well-tolerated， with the most common adverse reactions being mild-to-moderate gastrointestinal events， while potential risks including gallbladder events， pancreatitis， and mood changes require attention. In special populations， individualized assessment is warranted for use in children， elderly people， and pregnant women. Future research should focus on the screening of predictive biomarkers for efficacy， the development of long-acting oral formulations， and the accumulation of long-term safety follow-up data. |
| 期刊： | 2026年第37卷第16期 |
| 作者： | 罗成思；高蕊；朱艳娇；吴希超；何帅；宋智颖；李安安；周芃霖；李妍 |
| 英文作者： | LUO Chengsi， GAO Rui，ZHU Yanjiao，WU Xichao，HE Shuai，SONG Zhiying，LI An’an，ZHOU Penglin，LI Yan |
| 关键字： | 肠促胰素类药物；减重；肥胖症；代谢性疾病 |
| KEYWORDS： | incretin-based drugs;weight reduction;Obesity;metabolic diseases |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！